ozempic teeth: dentists warn of new glp-1 side effect How Drugs Like Ozempic May Impact Your Dental Health Ozempic teeth: Weight loss jabs

One of the biggest surprises was simply how fast and how powerfully these drugs work

Sources Lilly - What to know about retatrutide (updated March 2026) Lilly - TRIUMPH-4 Phase 3 retatrutide results on weight loss (December 11, 2025) Lilly - TRANSCEND-T2D-1 Phase 3 retatrutide results in type 2 diabetes (March 19, 2026) Lilly - TRIUMPH Phase 3 trial listing Jastreboff AM et al

The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review

Summary: Retatrutide is an investigational weight loss peptide and triple receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly that has not yet received MHRA or EMA marketing authorisation and remains unavailable through NHS or regulated UK prescribing pathways

In adults with T2D and either established ASCVD or multiple risk factors for ASCVD, we recommend use of: GLP-1RA or SGLT2i to reduce the risk of all-cause or CV mortality or MACE (Strong Recommendation